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Impact of pulmonary disease




Chronic obstructive pulmonary disease
(COPD) is highly prevalent and predictive
of worse outcomes in heart failure (HF)
with preserved ejection fraction (HFpEF).1,2
Severe COPD can result in cor pulmonale3
and worse outcomes in HF,2 while less severe
obstructive lung disease is associated with
impaired left ventricular filling and lower car-
diac output despite preserved left ventricular
ejection fraction (LVEF).4 We investigated
the influence of milder obstructive lung
disease – defined as the absence of use of
steroids or supplemental O2 – on cardio-
vascular (CV) outcomes among patients
with HFpEF enrolled in the Treatment of
Preserved Cardiac Function Heart Failure
with an Aldosterone Antagonist (TOPCAT)
trial in the Americas.
TOPCAT was a multicentre, randomized,
double-blind, placebo-controlled trial that
tested the efficacy of spironolactone to
reduce CV morbidity and mortality in 3445
adults ≥50 years of age with HFpEF (LVEF
≥45%).5 Key exclusion criteria relevant to this
analysis included severe lung disease requiring
home O2 or systemic steroid therapy, mod-
erate or severe pulmonary hypertension, and
directed therapy or biologics for lung disease.
Given the significant differences in population
characteristics and outcomes by region,6
we studied the 1767 patients recruited in
the Americas. All patients provided writ-
ten informed consent, and the study was
approved by local institutional review boards.
Outcomes included the composite of CV
death, aborted sudden death, or HF hospi-
talization (the TOPCAT primary outcome),
the individual components of this composite,
all-cause mortality, non-CV mortality, and
all-cause hospitalization.5 Pulmonary disease
was based on the report by the site investi-
gator of any diagnosis of COPD or asthma
at enrolment. Of 1765 patients enrolled in
the Americas and with data on pulmonary
disease status, 653 (37%) were included in
the TOPCAT echocardiographic study.7
Multivariable Cox proportional hazards
models were employed to relate pulmonary
disease at baseline to each outcome, adjusted
for age, female gender, white race, treat-
ment group, enrolment strata, percutaneous
coronary intervention, use of beta-blockers,
smoking status, body mass index, and heart
rate. We further adjusted for New York
Heart Association (NYHA) class in separate
models. Interaction between pulmonary
disease and randomized treatment assign-
ment (spironolactone vs. placebo) on clinical
outcomes was assessed using a multiplicative
interaction term.
The mean age was 72± 10 years, 50%
were women, and 22% were non-white. The
prevalence of COPD or asthma was 24%.
Patients with prevalent lung disease were
younger and more frequently non-white,
had higher prevalence of current smoking,
obesity, prior percutaneous coronary inter-
vention, and NYHA III/IV functional class,
and lower prevalence of beta-blocker use
(online supplementary Table S1). At a median
follow-up of 2.4 years, the primary composite
outcome occurred in 522 (30%), CV death in
223 (13%), HF hospitalization in 400 (23%),
all-cause mortality in 385 (22%), and all-cause
hospitalization in 1059 (60%). Prevalent pul-
monary disease was associated with a higher
risk of the primary composite endpoint,
related to higher risk of HF hospitalization
but not of CV death (Table 1). After adjust-
ment for demographics and co-morbidities,
associations persisted with the primary
composite endpoint, HF hospitalization and
all-cause hospitalization (Table 1).
In a post hoc exploratory analysis, pul-
monary disease at enrolment modified
the relationship between treatment with
spironolactone and subsequent CV mortality
(interaction P = 0.01) and all-cause mortal-
ity (interaction P = 0.02), such that the risk
reduction associated with spironolactone was
greater among patients compared to those
without pulmonary disease (Table 1). No
significant effect modification was observed
for the primary endpoint, HF hospitalization,
or all-cause hospitalization. Among patients
with pulmonary disease, those randomized
to spironolactone demonstrated a lower
prevalence of prior myocardial infarction and
higher prevalence of beta-blocker use (online
supplementary Table S2). Results remained
unchanged in models adjusting for random-
ization strata, and further adjusting for prior
myocardial infarction and beta-blocker use
(online supplementary Table S3).
Among 653 patients in the echocardio-
graphic study, 159 (24%) had pulmonary
disease (online supplementary Table S4). Pul-
monary disease was associated with greater
left ventricular wall thickness and left ven-
tricular hypertrophy prevalence, higher LVEF
and tissue Doppler imaging s’, and smaller
left atrial volume index in unadjusted analysis.
Only associations with LVEF, tissue Doppler
imaging s’, and left atrial volume index per-
sisted after accounting for age, sex, and race
(online supplementary Table S5).
In this analysis of HFpEF patients enrolled
in TOPCAT in the Americas, obstructive lung
disease was independently associated with
a heightened risk of the primary composite
outcome, HF hospitalization alone, and all-
cause hospitalization. Despite this, pulmonary
disease was associated with higher LVEF and
smaller left atrial volume index, without
differences in right ventricular function or
pulmonary pressure, suggesting an important
role for extracardiac factors in mediating the
observed increase in risk. In an exploratory
post hoc analysis, obstructive lung disease
modified the relationship of randomized
treatment with all-cause and CV mortality,
but not with the TOPCAT primary endpoint.
Similar findings were observed in the
I-PRESERVE trial, where COPD prevalence
was an independent predictor of HF death or
hospitalization.8 Potential mechanisms linking
COPD to increased risk of HF hospitalization
in HFpEF include misdiagnosis of less severe
COPD as a HF exacerbation due to over-
lapping signs and symptoms,1 or to lower
cardiopulmonary reserve in patients with
combined HFpEF and obstructive pulmonary
disease leading to a lower threshold for HF
or respiratory decompensation resulting in
an increased likelihood of hospitalization.
One possible explanation for the finding
of effect modification of baseline pulmonary
disease on treatment effect for CV and all-
cause mortality is chance, given the post hoc
nature of this analysis. However, pulmonary








































































































































































































































Table 1 Clinical outcomes in patients without (n = 1349) and with (n = 416) concomitant pulmonary disease, and the
effect of randomized treatment allocation (spironolactone vs. placebo), at a median follow-up of 2.4 (25th–75th
percentile: 1.4–3.9) years
Outcomes Risk associated with PD Effect of randomized treatment allocation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Events HR (95% CI) Adj. HR Spironolactone Placebo HR (95% CI) P-value for
(95% CI)b Events Events (reference: interaction
placebo)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary composite
outcome
Without PD 376 (28%) Ref. Ref. 178 (27%) 198 (29%) 0.87 (0.72–1.08) 0.11




64 (29%) 82 (41%) 0.65 (0.47–0.91)
All-cause mortality
Without PD 281 (21%) Ref. Ref. 136 (20%) 145 (21%) 0.95 (0.75–1.20) 0.02




42 (19%) 62 (31%) 0.57 (0.38–0.84)
CV mortality
Without PD 161 (12%) Ref. Ref. 76 (11%) 85 (12%) 0.92 (0.67–1.25) 0.01




20 (9%) 42 (21%) 0.39 (0.23–0.67)
Non-CV mortalitya
Without PD 88 (6%) Ref. Ref. 48 (7%) 40 (6%) 1.23 (0.81–1.87) 0.61




19 (9%) 16 (8%) 1.03 (0.53–2.00)
All-cause
hospitalization
Without PD 775 (57%) Ref. Ref. 382 (57%) 393 (58%) 0.98 (0.85–1.13) 0.06




142 (66%) 142 (72%) 0.76 (0.60–0.96)
HF hospitalization
Without PD 285 (21%) Ref. Ref. 128 (19%) 157 (23%) 0.81 (0.64–1.02) 0.96




56 (26%) 59 (30%) 0.80 (0.55–1.15)
CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; PD, pulmonary disease.
Aborted cardiac arrest was not individually considered because of six events only. When New York Heart Association class was added to this model, only the association
of PD with HF hospitalization (HR 1.28, 95% CI 1.03–1.60; P = 0.03) and all-cause hospitalization (HR 1.28, 95% CI 1.11–1.47; P< 0.01) persisted. Randomization among
patients without PD (668 spironolactone; 681 placebo) and with PD (218 spironolactone; 198 placebo).
aUnequivocal and documented non-CV primary cause of death; unknown causes were not considered.
bAdjusted for age, female gender, white race, treatment group, previous HF hospitalization strata, current smoking, percutaneous coronary intervention, use of beta-blockers,
body mass index, and heart rate on electrocardiogram.
gas diffusion is reduced in HFpEF9 and is
abnormal in the majority with coexistent
COPD and HFpEF.10 This is possibly due
to processes mediated by aldosterone and
modifiable with mineralocorticoid recep-
tor antagonists, including COPD-associated
reduction in alveolar surface area and HF-
associated proliferation of alveolar type II
cells, thickening of the alveolar–capillary
interstitium, and lung fibrosis. In HF with
reduced ejection fraction, spironolactone
improves lung diffusion capacity, potentially
via aldosterone receptor inhibition on alve-
olar epithelium and endothelium cells.11
Further studies are necessary to determine
whether such an effect exists in patients with
both HFpEF and COPD.
Limitations of this analysis include ascer-
tainment of pulmonary disease from medical
history, and not confirmed by pulmonary
function testing; potential misdiagnosis of
COPD exacerbation as decompensated HF
resulting in overestimation of CV events
among patients with obstructive lung disease;
and potential limited generalizability of our
results from a clinical trial sample.
We conclude that pulmonary disease
independently predicts HF and all-cause
hospitalizations, but not mortality, in HFpEF.
Pulmonary disease is not associated with
prominent alterations in cardiac structure
and function, suggesting an important role for
extracardiac factors in mediating this risk.
Supplementary Information
Additional supporting information may be
found online in the Supporting Information
section at the end of the article.
Table S1. Baseline clinical character-
istics in the study sample overall and
stratified by the presence of pulmonary
disease.
Table S2. Baseline clinical characteristics,
stratified by the presence of pulmonary








































































































































































































































disease and randomization treatment
assignment.
Table S3. Impact of randomized treat-
ment allocation (spironolactone vs.
placebo) on outcomes in patients without
pulmonary disease (668 on spironolactone
and 681 on placebo) and with pulmonary
disease (218 on spironolactone and 198
on placebo).
Table S4. Baseline clinical characteristics
among TOPCAT Americas patients in the
echocardiographic substudy stratified by
the presence of pulmonary disease.
Table S5. Cardiac structure and function
among TOPCAT Americas patients in the
echocardiographic substudy, overall and
stratified by the presence of pulmonary
disease.
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Body fat phenotypes and
treatment response to
spironolactone in ambulatory
patients with heart failure
and preserved ejection
fraction: a post-hoc analysis
of the Aldo-DHF trial
Obesity and heart failure (HF) with preserved
ejection fraction (HFpEF) often co-exist,
are increasingly prevalent and with rising
incidence.1 Recent reports have suggested
that the development of HFpEF is associated
with a systemic proinflammatory state related
to commonly coexisting conditions such as
obesity, diabetes, hypertension, and the habit
of smoking.2
In patients enrolled in the TOPCAT
(Treatment of Preserved Cardiac Function
Heart Failure with an Aldosterone Antag-
onist) trial, those with abdominal obesity
had higher event rates, including cardiovas-
cular death.3 In TOPCAT, spironolactone
reduced the primary outcome of HF hos-
pitalization or cardiovascular death in the
reliable patient cohort from the ‘Americas’,
who showed unquestioned HF signs and
symptoms (and event rates compatible with
HFpEF) as well as detectable serum levels
of spironolactone metabolites.4,5 In con-
sequence, spironolactone received a class
IIa indication for the treatment of HFpEF
in the updated American College of Car-
diology/American Heart Association/Heart
Failure Society of America guidelines.6 In
TOPCAT, no treatment effect modifica-
tion (i.e. ‘interaction’) was found between
spironolactone and the obesity parameters,
including body mass index (BMI) and waist
circumference (WC), with regard to the
study outcomes (P for interaction >0,1).3
In a post-hoc analysis of the EMPHASIS-
HF (Eplerenone in Patients with Systolic
Heart Failure and Mild Symptoms) trial that
enrolled patients with HF and a reduced
ejection fraction (HFrEF), eplerenone might
have been more effective in patients with
abdominal obesity.7 The ‘effect modifi-
cation’ by abdominal obesity could have
been specific of HFrEF in comparison to
HFpEF patients but needs further valida-
tion in different cohorts. To clarify these
observations we studied the relationship
© 2020 European Society of Cardiology
